Drug Profile
Insulin - Albireo Pharma
Alternative Names: BIOD-531; Concentrated ultra-rapid-acting insulin - Albireo PharmaLatest Information Update: 06 Mar 2023
Price :
$50
*
At a glance
- Originator Biodel
- Developer Albireo Pharma
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 06 Nov 2018 Discontinued - Phase-II for Type-2 diabetes mellitus (Combination therapy) in USA (SC)
- 06 Nov 2018 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (SC)